Media Release

5 December 2025

Amsulostat data to be presented at 67th American Society of Hematology Annual Meeting

Syntara Limited (ASX: SNT), a clinical-stage drug development company, is pleased to announce that two posters detailing the preclinical findings and clinical data[1] from its Phase 2a trial evaluating amsulostat (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF) will be presented at the 67th American Society of Hematology Annual Meeting (ASH), taking place in Orlando, Florida, from 6-9 December 2025.

One poster presentation, titled *"A Phase 1/2a Trial of Amsulostat, a Novel Pan-Lysyl Oxidase Inhibitor, in Patients with Advanced Myelofibrosis as an Add-On to Ruxolitinib Treatment for Up to 52 Weeks,"* will be featured in the session *"Myeloproliferative Syndromes: Clinical and Epidemiological"* on Saturday 6 December (EST).

In a concurrent *"Bone Marrow Microenvironment"* session, Syntara will also present preclinical research highlighting amsulostat-sensitive, lysyl oxidase–mediated modulation of growth factor signaling, titled *"Lysyl Oxidases Directly Control Cell Surface Abundance of Platelet-Derived Growth Factor Receptors and Signaling in Osteoblasts."*

Attending the ASH Annual Meeting on behalf of Syntara will be Dr. Jana Baskar, CMO, Dr. Wolfgang Jarolimek, Head of Drug Discovery, and Gary Phillips, CEO.

Mr Phillips said: *"The ASH Annual Meeting and Exposition is the leading global forum for advancing research in haematological malignancies. We welcome the opportunity to present our recent clinical and mechanism of action data on amsulostat to the global haematology community and to discuss future clinical and commercial pathways with potential collaborators."*

Syntara has received feedback from the US Food and Drug Administration (FDA) on the recommended pathway for further development of amsulostat and, with the support of an experienced and well renowned advisory board, is progressing the protocol for the next trial. Amsulostat is also being evaluated in two Phase 1c/2 trials of myelodysplastic syndrome which are currently recruiting and expected to deliver preliminary results in 2026.

#ENDS#

1. Poster contains data from the same database as used to report top line results in ASX release on 30 September 2025. Posters will be made available on the Syntara website.

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

SOURCE:
Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST HERE